Employees: 109
Size Janux Therapeutics (JANX) is a United States Health Care company (Biotechnology) with a market value of $631M, the 2523rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.31 on 18 Nov 2026.
Performance Over six months the shares fell 28.4%, against -12.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 132.9% over the last twelve months (peer median +18.4%); the operating margin is -599.3% (peer median -92.0%).
Short interest Short interest is 8.7% of the free float (30 Oct 2026).
Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $23.3M | $10.0M | $10.6M | $8.08M | $8.61M |
| Revenue growth | — | -6% | +31% | -6% | — |
| Gross profit | $21.4M | $7.97M | $8.53M | $6.13M | $7.77M |
| EBITDA | -$138M | -$156M | -$96.8M | -$71.0M | -$66.2M |
| Net income | -$99.8M | -$114M | -$69.0M | -$58.3M | -$63.1M |
| Free cash flow | -$54.2M | -$83.3M | -$44.2M | -$52.4M | -$49.4M |
| Capital expenditure | $583,000 | $1.04M | $359,000 | $1.85M | $6.45M |
| Total debt | $20.4M | $22.1M | $23.0M | $24.5M | $25.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JANX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -40.1% | -10.6% | lowest of 21 |
| 6-month return | -28.4% | -12.9% | 6th lowest of 20 |
| Distance from 52-week high | -70.8% | -44.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | +132.9% | +18.4% | 6th highest of 17 |
| Operating margin | -599.3% | -92.0% | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | 3.2× | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |